

RESEARCH ARTICLE

Open Access

Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia

Domenica Ronchetti¹, Laura Mosca¹, Giovanna Cutrona², Giacomo Tuana³, Massimo Gentile⁴, Sonia Fabris¹, Luca Agnelli^{1,3}, Gabriella Ciceri¹, Serena Matis⁵, Carlotta Massucco⁵, Monica Colombo⁵, Daniele Reverberi⁶, Anna Grazia Recchia⁴, Sabrina Bossio⁴, Massimo Negrini⁷, Pierfrancesco Tassone⁸, Fortunato Morabito⁴, Manlio Ferrarini⁵ and Antonino Neri^{1,3*}

Abstract

Background: Small nucleolar RNAs (snoRNAs) and small Cajal body-specific RNAs are non-coding RNAs involved in the maturation of other RNA molecules. Alterations of sno/scaRNA expression may play a role in cancerogenesis. This study elucidates the patterns of sno/scaRNA expression in 211 chronic lymphocytic leukemia (CLL) patients (Binet stage A) also in comparison with those of different normal B-cell subsets.

Methods: The patterns of sno/scaRNA expression in highly purified CD19⁺ B-cells of 211 CLL patients and in 18 normal B-cell samples - 6 from peripheral blood, and 12 from tonsils (4 germinal center, 2 marginal zone, 3 switched memory and 3 naïve B-cells) - were analyzed on the Affymetrix GeneChip® Human Gene 1.0 ST array.

Results: CLLs display a sno/scaRNAs expression profile similar to normal memory, naïve and marginal-zone B-cells, with the exception of a few down-regulated transcripts (SNORA31, -6, -62, and -71C). Our analyses also suggest some heterogeneity in the pattern of sno/scaRNAs expression which is apparently unrelated to the major biological (ZAP-70 and CD38), molecular (*IGHV* mutation) and cytogenetic markers. Moreover, we found that SNORA70F was significantly down-regulated in poor prognostic subgroups and this phenomenon was associated with the down-regulation of its host gene *COBLL1*. Finally, we generated an independent model based on SNORA74A and SNORD116-18 expression, which appears to distinguish two different prognostic CLL groups.

Conclusions: These data extend the view of sno/scaRNAs deregulation in cancer and may contribute to discover novel biomarkers associated with the disease and potentially useful to predict the clinical outcome of early stage CLL patients.

Background

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease. Some patients have an indolent course and may survive for years without treatment, while others have an aggressive and rapidly progressive course [1,2]. Although the current Rai [3] and Binet [4] staging systems identify patients with high-risk disease, they do not prospectively distinguish patients with potentially evolving disease from those destined to remain stable for decades.

A number of cellular and molecular markers help to classify CLL into biologically and clinically distinct subgroups, and to predict the clinical course of the disease at diagnosis [5]. CLL patients with unmutated (UM-CLL) immunoglobulin heavy chain variable (*IGHV*) region genes (>98% homology to germline sequences), increased expression of the CD38 cell surface antigen, or of the 70-kd zeta-chain T-cell receptor-associated protein kinase (ZAP-70) experience a shorter therapy-free interval, a more aggressive clinical course, and a shorter survival [6-8]. Specific recurrent chromosomal abnormalities, traditionally detected by Fluorescence *in situ* Hybridization (FISH), such as deletions at 13q14 (del13), 11q23 (del11), 17p13 (del17), and trisomy 12 (12+) may also represent

* Correspondence: antonino.neri@unimi.it

¹Department of Clinical Sciences and Community Health, University of Milano, Milano, Italy

³Department of Clinical Sciences and Community Health, University of Milan, Hematology 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, F. Sforza, 35-20122, Milano, Italy

Full list of author information is available at the end of the article

important independent biomarkers for disease progression and survival [9-13].

In recent years, the discovery of non-coding RNAs (ncRNAs) has provided new tools for the understanding of cancer biology [14]. ncRNAs are functional transcripts that do not code for proteins, but indeed play a major role in regulating gene expression at virtually all levels. Among these, small nucleolar RNAs (snoRNAs) are molecules of 60–300 nucleotides in length that function as guide RNAs for the post-transcriptional methylation and/or pseudouridylation of ribosomal RNAs. Unlike snoRNAs, small Cajal body-specific RNAs (scaRNAs) accumulate within the Cajal bodies (i.e. conserved subnuclear organelles that are present in the nucleoplasm) and can guide both post-transcriptional modifications of small nuclear RNAs. sno/scaRNAs can also target other RNAs including mRNAs. However, a subgroup of so-called “orphan” sno/scaRNAs exists whose function remain to be clarified. Notably, in vertebrates most sno/scaRNAs reside in the introns of protein-coding host genes and are processed out of the excised introns [15].

Experimental evidence has recently shown that sno/scaRNAs dysfunction may have a role in the origin of human cancers [16]. Limited data concerning the involvement of sno/scaRNAs in hematological malignancies have been reported only very recently by us and others [17-22], and are lacking in CLL.

In the present study, we investigated the sno/scaRNA expression profiling in a large and representative prospective series of Binet stage A CLL patients. In addition, we evaluated sno/scaRNAs expression in comparison to that observed in various sub-populations of normal B-cells from tonsils and peripheral blood B-lymphocytes. Finally, the sno/scaRNA expression pattern was correlated with clinical data in order to outline their possible role in CLL prognosis.

Methods

Patients

Two hundred and eleven newly diagnosed CLL patients were prospectively enrolled from several Italian Institutions in an observational multicenter study (O-CLL1 protocol, clinical trial.gov identifier NCT00917540) from January 2007 to May 2011. The National Cancer Institute (NCI)-sponsored Working Group guidelines were followed for diagnosis and staging [23]. All patients had an absolute lymphocyte count (ALC) greater than $5000 \times 10^9/L$ in the peripheral blood. Exclusion criteria were the following: i) a CLL diagnosis exceeding 12 months before registration; ii) a leukemic phase of lymphoproliferative disorders of B origin, CD5⁺ and/or CD23⁺ according to flow cytometry analysis; iii) a clinical Binet stage B or C; iv) need of therapy according to NCI guidelines and v) age > 70 years. The median follow-up of this series was 30 months. Diagnosis was

confirmed by the biological review committee according to flow cytometry analysis centralized at the National Cancer Institute (IST) Laboratory in Genoa. Written informed consent was obtained from all patients in accordance with the declaration of Helsinki and the study was approved by the local Ethics Review Committee (Comitato Etico Provinciale, Modena, Italy).

Peripheral blood mononuclear cells from CLL patients and normal control, and B-cell sub-populations from tonsils (i.e. naïve B-cells (N), marginal zone (MZ)-like, germinal center (GC) and switched memory (SM) B-cells) were obtained as described in Additional file 1 and Additional file 2.

Biological and molecular analyses were performed in highly enriched CD19⁺ B-cells as previously described [24,25]. CD38 and ZAP-70 expressions were investigated using a cut-off of 20% and 30% respectively to discriminate positive from negative patients. Del11, del13, del17, and 12+, *IGHV* mutation status and stereotyped BCR subtypes were determined as previously described [26-28]. Specifically, *IGHV* sequences from 210 patients were submitted to IMGT V-QUEST analysis software, and were classified as mutated (M-CLL) or UM-CLL using a discriminating mutation cut-off percentage at 2%.

Gene expression profiling (GEP)

Total RNA from purified CD19⁺ B-cells of 211 CLL cases and 18 normal B-cell samples - 6 from peripheral blood, and 12 from tonsils (4 germinal center, 2 marginal zone, 3 switched memory and 3 naïve B-cells) - were analyzed on the GeneChip® Human Gene 1.0 ST array (Affymetrix Inc., Santa Clara, CA). The raw intensity expression values were processed by Robust Multi-array Average (RMA) procedure [29] with the re-annotated Chip Definition Files (CDF) from BrainArray libraries version 15.0.0 [30] available at <http://brainarray.mbni.med.umich.edu>. This custom CDF reorganized probe sets based on i) more stringent gene/transcript definitions from UniGene database, and ii) alignment analyses performed on each single probe included in the probeset [30]. The updated annotations provided a better precision and accuracy in transcript expression level estimates compared to the original Affymetrix definitions [19,31].

Supervised analyses were carried out using the Significant Analysis of Microarrays software version 4.00 (SAM; excel front-end publicly available at <http://www-stat.stanford.edu/~tibs/SAM/index.html>) [32]. The cutoff point for statistical significance (at a *q*-value 0) was determined by tuning the Δ parameter on the false discovery rate and controlling the *q*-value of the selected probes. Hierarchical agglomerative clustering of the most significant probesets found was performed adopting Pearson and average as distance and linkage methods, respectively. DNA-Chip Analyzer software (dChip) [33] was used to perform

clustering and to graphically represent it. GEP data have been deposited in the NCBI Gene Expression Omnibus database (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under accession #GSE46261.

In order to explore the distribution of CLL samples we applied principal component analysis (PCA) on sno/scaRNA microarray expression data. PCA was performed by means of the *princomp* function in R software, by scaling data and using the associated correlation matrix. Hence we used the *3dplot* to visualize samples by the first three principal components.

Statistical analysis

We used the Cox proportional hazards model in the *globaltest* function of R software (with 100,000 permutation) to test the association (positive or negative) between sno/scaRNA expression levels, assumed as continuous variables and progression free survival (PFS) as clinical outcome. The list of significant associated sno/scaRNA to the PFS was reduced to derive a smaller prognostic sno/scaRNA signature by employing single sno/scaRNA expression profile. Unsupervised K-means clustering was applied to each sno/scaRNA to define a threshold splitting samples with higher expression from those with lower expression (Additional file 3), in order to test their different clinical outcome. The survival distributions of patient groups identified by this approach were tested using the Kaplan-Meier estimator and log-rank test, and P-values were calculated according to the standard normal asymptotic distribution (*survdiff* function of the *survival* R package). The Benjamini-Hochberg correction has been applied to consider the false discovery rate that incurred in the multiple testing. Independence between commonly used CLL prognostic factors (*IGHV* mutational status, ZAP-70, CD38 and unfavorable chromosome aberrations, namely del11, del17 and 12+) and sno/scaRNAs signature was assessed using multivariate Cox proportional-hazards regression procedure by the *coxph* function in the *survival* R package. The robustness of the 2-snoRNA model was tested using the linear discriminant analysis for the classification of multivariate observations, with leave-one-out procedure, using *lda* function in *MASS* R package. Other statistical procedures were applied using standard functions in *base* R package (Kendall Tau correlations and Wilcoxon rank-sum tests).

Results

Characteristics of CLL patients

Two hundred eleven CLL patients at Binet stage A were included in the study; most of them were Rai 0 stage (74.4%). The median follow-up was 30 months (range 1–65 months). CLL cell samples were characterized for *IGHV* somatic mutations, ZAP-70 and CD38 expression and the presence of typical chromosomal aberrations

(del13, del11, del17, and 12+) detected by FISH analysis. Table 1 summarizes the features of CLL samples.

sno/scaRNA expression profile of CLL cells compared to normal B-cell populations

The expression profiles of sno/scaRNA genes were investigated using Human Gene 1.0 ST arrays. Oligonucleotide probes were mapped according to the genome and transcriptome information from the human genome build release GRCh37/hg19 (see Methods) identifying 215 human snoRNA (76 SNORA and 139 SNORD transcripts) and 17 human scaRNA genes. The expression patterns also were studied in normal B-cells from peripheral blood (pBC) and in different tonsil B-cell sub-populations including germinal center (GC), naïve (N), marginal zone (MZ) and memory (SM) B-cells (Additional file 2 reports the FACS sorting strategy used to purify these cell subpopulations as described in Additional file 1).

At first, we applied PCA on the sno/scaRNA dataset composed by 211 CLL and 18 normal cell samples; the first three PCs contained 51% of variance in our data and we used them to display all the cell type samples in a three-dimensional plot. As shown in Figure 1A, we observed that CLL, N, MZ and SM B-cell samples were clustered together, whereas GC and in particular pBC

Table 1 Characteristics of CLL patients cohort

	CLL (% of total)
N° of patients	211
Rai stage	
0	157 (74.4)
I	40 (19)
II	14 (6.6)
CD38	
Negative	148 (70.1)
Positive	63 (29.9)
ZAP-70	
Negative	115 (54.5)
Positive	96 (45.5)
IGHV	
M-CLL	127 (60.2)
UM-CLL	83 (39.3)
nd	1 (0.5)
FISH	
No abnormality	76 (36)
del13	102 (48.3)
12+	28 (13.2)
del11	16 (7.6)
del17	5 (2.4)


samples, were well-separated from other groups along PC3 and PC1 components, respectively. Based on this evidence, multiclass analysis was performed comparing CLLs with N, MZ and SM (taken as a single group) and GC B-cells. Despite the heterogeneity of snoRNAs expression in CLL samples, we confirmed that the sno/scaRNA expression profile of CLL was much more similar to N-MZ-SM B-cells rather than to GC (Figure 1A-B). Specifically, we observed the significant down-regulation of SNORA31, -6, -62, and 71C, SNORD37, and -50B in CLL with respect to tonsillar B-cells; however, GC B-cells differed from both CLL and N-MZ-SM B-cells on the basis of a number of down-regulated transcripts, such as SNORD116-1, -116-23, -116-29, -94, and SNORA36A (Figure 1B).

Notably, SNORA31, -6, -62, and -71C also resulted significantly down-regulated in each of the CLL subgroups stratified according to genetic lesions (del13, del11, del17, 12+ and FISH negative) in a two-class supervised analysis with the N, MZ and SM group (data not shown). Finally, in agreement with PCA, supervised analysis confirmed the strong differences in sno/scaRNA expression between pBC and CLL samples, showing the up-regulation of 102 sno/scaRNAs and the down-regulation of a single transcript (SNORA36C) in CLL patients (Additional file 4).

Global sno/scaRNA expression profiling in CLL patients

To determine whether the natural grouping of global sno/scaRNA expression profiling could be associated with particular CLL subgroups, we performed an unsupervised analysis using conventional hierarchical agglomerative clustering of 71 snoRNAs and 9 scaRNAs, the average change of which varied at least 1.5-fold in the expression levels from the mean values across the dataset (Additional file 5 and Additional file 6). However, CLL samples appeared scattered along the dendrogram irrespective of any known molecular characteristic.

Consequently, we performed supervised analyses (q value = 0) to investigate the occurrence of specific sno/scaRNA expression patterns in CLL groups stratified according to the presence/absence of different prognostic markers; i.e. *IGHV* gene mutations and ZAP-70 and CD38 expression. Significant differences were detected only in the expression of a limited number of transcripts in the groups stratified as above (Table 2). Specifically, UM-CLLs showed the down-regulation of SNORA70F and SNORA70C, and the up-regulation of SNORA71C. Of note, SNORA70F also was found down-regulated in ZAP-70 positive and in CD38 positive CLL patients, in whom SNORA70C was also down-regulated. Furthermore,



snoRNAs expression was investigated in cases stratified according to the presence of chromosomal alterations such as 12+, del11, del13, and del17 by supervised analyses (at q value = 0). SNORA70F was significantly down-regulated in CLL patients with 12+ or del11 (Table 2). Overall, lower expression levels of SNO-RA70F were associated with the cumulative adverse biological and molecular features (see Additional file 7). Moreover, 12+ patients displayed the significant down-regulation of SCARNA17 and up-regulation of three snoRNAs located on chromosome 12 (SNORA2B, SNORD59A, and -59B) (Table 2). The significant down-

regulation of SCARNA9 which is located at 11q21 (Table 2), was also observed in cases with del11. Interestingly, in 8/13 del11 cases, for which genome-wide data were available, we observed that the SCARNA9 locus was included in the deleted region (data not shown). By comparing patients with/without del13 we identified 17 snoRNAs and 2 scaRNAs consistently down-regulated in del13 samples (Table 2). Finally, supervised analysis of CLL samples with del17 did not show any differentially expressed sno/scaRNAs, a finding that could be, however, related to the low number of cases.

Table 2 Supervised analysis comparing CLLs with adverse vs favorable prognostic factors

NEGATIVE PROGNOSTIC FACTOR	sno/scaRNA	Alias	Cytoband	Score(d)	Fold change
IGHV unmutated	SNORA70F	U70F	2q24	-10.81	0.30
	SNORA70C	U70C	9q33	-3.58	0.87
	SNORA71C	U71C	20q11	3.54	1.23
ZAP70 pos	SNORA70F	U70F	2q24	-6.91	0.43
CD38 pos	SNORA70F	U70F	2q24	-6.67	0.41
	SNORA70C	U70C	9q33	-3.46	0.86
12+	SNORA70F	U70F	2q24	-3.88	0.46
	SCARNA17	mgU12-22/U4-8	18q21.1	-3.58	0.72
	SNORD59A	U59	12q13.3	3.58	1.38
	SNORA2B	ACA2B	12q13.11	3.69	1.40
del11	SNORA70F	U70F	2q24	-4.00	0.37
	SCARNA9	mgU2-19/30	11q21	-3.75	0.62
	SNORA16A	ACA16	1p35	-5.24	0.62
del13	SNORA70G	U70G	12q15	-4.98	0.80
	SNORA24	ACA24	4q26	-4.87	0.65
	SNORD38A	U38A	1p34	-4.53	0.77
	SNORA20	ACA20	6q25	-4.34	0.74
	SNORD60	U60	16p13	-4.34	0.63
	SNORD54	U54	8q12	-4.31	0.73
	SNORD50A	U50	6q14	-4.28	0.70
	SNORD45B	U45B	1p31	-4.21	0.57
	SNORD76	U76	1q25	-4.20	0.75
	SNORD34	U34	19q13	-4.14	0.75
	SCARNA7	U90	3q25	-4.08	0.79
	SNORD8	mgU6-53	14q11	-4.06	0.74
	SNORD15B	U15B	11q13	-4.02	0.73
	SNORD38B	U38B	1p34	-4.00	0.69
	SNORD59B	U59B	12q13	-3.98	0.78
	SNORD104	U104	17q23	-3.88	0.77
	SNORA68	U68	19p13	-3.76	0.79
SCARNA10	U85	12p13	-3.68	0.76	

Abbreviations: scaRNA small Cajal body-specific RNA, snoRNA small nucleolar RNA.

Correlation of sno/scaRNAs expression levels with those of their corresponding host genes

The vast majority of human sno/scaRNAs are encoded sense-oriented in introns of so-called host genes, and are produced by exonucleolytic processing of the debranched intron after splicing. This suggests that sno/scaRNAs and their host genes may have a coordinate expression. Among 169 sno/scaRNA-host gene couples present on Human Gene 1.0 ST array, we identified by means of the non parametric Kendall τ correlation test, 75 snoRNAs and 4 scaRNAs whose expression levels were significantly correlated with those of their corresponding host genes (Additional file 8); this list includes 15 sno/scaRNAs resulting from the supervised analyses carried out in our study (Table 3). Specifically, SNORA2B and the SNORD59A, -59B cluster, all of which located at 12q13, were up-regulated in patients with 12+ together with their corresponding host transcripts *c12orf41* and *ATP5B* (mitochondrial ATP synthase). Similarly, the expression of SNORA31, which is located at 13q14, was correlated with that of the host gene *TPT1*. Notably, the expression of SNORA70F was significantly associated with that of its host gene *COBLL1*, whereas the expression of the SNORA6 and -62 cluster was significantly correlated with that of its host gene *RPSA*.

Identification of sno/scaRNA transcriptional profile with clinical relevance in the definition of high-risk CLLs

The sno/scaRNAs transcriptional profiles were examined in relation to CLL clinical course in 191/211 CLL patients for whom clinical follow-up was almost 6 months. In particular, we evaluated whether a specific sno/scaRNA signature was significantly associated with PFS in our prospective series. To this aim, we determined possible associations between PFS and each of the 80 most variable sno/scaRNAs across the CLL dataset (*i.e.* sno/scaRNAs whose average ratio of the expression was at least 1.5 folds above the mean values). Of these 80 sno/scaRNAs, 5 showed significant association with PFS ($P < .05$, see Additional file 5), *i.e.* SNORD116-18, SNORA70F, SNORA74A, SNORD56, and SNORD1A.

As a further validation, the expression levels of SNORD1A, and SNORA74A were evaluated in 50 samples by quantitative real time PCR (qRT-PCR) as previously described [19]: the linear correlation analysis indicated a good correspondence between the two techniques (Pearson's correlation coefficient of 0.71 and 0.76, respectively; data not shown).

Therefore, we focused on each of the 5 snoRNAs as unique predictive factor. Based on the K-means clustering stratification of CLL cases into two groups according to snoRNAs expression level, we found that each snoRNA resulted capable of providing significant predictive value

related to PFS in the univariate log-rank test ($P < .05$, Table 4). However, in multivariate analysis, only SNORA74A, SNORD116-18 and SNORD56 retained their independence (Additional file 9). Specifically, high expression of SNORA74A and SNORD116-18, and low expression of SNORD56 were associated with shorter PFS. We therefore focused on SNORA74A and SNORD116-18, whose ratio between median high- and low-expression levels exceeded two-fold (Additional file 3), to evaluate whether their combination could improve the robustness of the single-snoRNA model, based on the scheme of three groups defined by (i) high/high, (ii) low/low or (iii) discordant expression levels. Significantly, better PFS was identified in patients with the concomitant low expression of SNORA74A and SNORD116-18, whereas no difference emerged between the two other groups, namely those including patients with high expression of both or one of the two snoRNAs (data not shown). Based on these findings, we could define a low-risk group that included 110 patients (58%) characterized by the low expression of both snoRNAs, and a high-risk group (81 patients) characterized by the high expression of at least one of the two snoRNAs. The high-risk group had a hazard ratio of 2.53 (95% CI: 1.48-4.32) and a median PFS of 39 months (Table 5 and Figure 2), versus a median PFS not reached in low-risk group. The robustness of the 2-snoRNA model was tested by leave-one-out cross validation procedure, which ultimately led to near 90% accuracy.

Multivariate Cox regression analysis was finally performed to test the independence of the 2-snoRNAs risk model from known predictive factors in CLL (*IGHV* mutational status, ZAP-70 and CD38 expression and unfavorable chromosomal aberration) as covariates. The analysis ascertained the independent prognostic value of the 2-snoRNAs model in our series ($p = 0.0007$, Table 5).

Discussion

The relevance of non-coding RNA sequences in human disease has increased remarkably over the past years. miRNAs represent the most extensively investigated category of ncRNAs in cancer since there are genetic and epigenetic defects causing their deregulation and contributing to tumorigenesis. However, other ncRNAs, such as PIWI-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), transcribed ultraconserved regions (T-UCRs) and large intergenic non-coding RNAs (lincRNAs) are emerging as key elements of cellular homeostasis. The deregulation of these RNAs may contribute to the development of many different human disorders, including cancer [14].

snoRNAs and scaRNAs play important roles in the maturation of rRNA, tRNA, snRNA as well as in mRNA biogenesis [34]. sno/scaRNAs may also be involved in human cancers as demonstrated by recent studies in MM,

lymphomas and leukemias [17-22]. In this report we describe for the first time the global expression profiles of sno/scaRNAs in the cells from a large cohort of CLL cases already characterized for many features. These profiles were also compared with those of various sub-populations of normal B-cells from peripheral blood and from tonsils.

The identification of the normal B-cell counterpart of CLL (namely SM and MZ B-cells on one side and N B-cells on the other) is currently a debated question [35,36]. Although based on a limited number of normal samples, our analysis revealed that the sno/scaRNA expression profile of leukemic cells is much more similar to N, MZ and M B-cells than to GC or total pB- cells. Therefore, sno/

Table 3 Correlation of expression levels of sno/scaRNAs resulting from multiclass or supervised analyses and corresponding host-genes

Sno/scaRNA	Alias	Cytoband	Host gene	Kendall <i>q</i> -value	Target RNA
SNORD45B	U45B	1p31.1	RABGGTB	7.260E-14	18S rRNA A159 and 18S rRNA U172
SNORD38A	U38A	1p34	RPS8	A ^a	28S rRNA A1858
SNORD38B	U38B	1p34	RPS8	A ^a	28S rRNA A1858
SNORA16A	ACA16	1p35.3	SNHG12	2.540E-02	28S rRNA U4412
SNORD76	U76	1q25	GAS5	A ^a	28S rRNA A2350
SNORD94	U94	2p11.2	PTCD3	5.609E-01	U6 snRNA C62
SNORA70F	U70F	2q24	COBLL1	<2.2e-16	18S rRNA U1692
SNORA6	ACA6	3p22	RPSA	4.180E-06	28S rRNA U3616
SNORA62	E2	3p22	RPSA	6.380E-06	28S rRNA U3830 and 28S rRNA U3832
SCARNA7	U90	3q25	KPNA4	8.912E-01	U1 snRNA A70
SNORA24	ACA24	4q26	SNHG8	A ^a	18S rRNA U863 and 18S rRNA U609
SNORD50A	U50	6q14	SNHG5	A ^a	28S rRNA C2848 and 28S rRNA G2863
SNORA20	ACA20	6q25	TCP1	1.000E+00	18S rRNA U651
SNORD54	U54	8q12.1	RPS20	<2.2e-16	18S rRNA G644
SNORA70C	U70C	9q33.1	ASTN2	3.760E-06	18S rRNA U1692
SNORD15B	U15B	11q13.4	RPS3	<2.2e-16	28S rRNA A3764
SCARNA9	mgU2-19/30	11q21	KIAA1731	1.050E-01	U2 snRNA G19 and U2 snRNA A30
SCARNA10	U85	12p13	NCAPD2	3.746E-01	U5 snRNA U46 and U5 snRNA C45
SNORA2B	ACA2B	12q13.11	C12orf41	<2.2e-16	28S rRNA U4263 and 28S rRNA U4282
SNORD59B	U59B	12q13.3	ATP5B	3.530E-07	18S rRNA A1031
SNORD59A	U59	12q13.3	ATP5B	9.032E-04	18S rRNA A1031
SNORA70G	U70G	12q15	RAB1B	1.000E+00	18S rRNA U1692
SNORA31	ACA31	13q14.13	TPT1	2.951E-02	18S rRNA U218 and 28S rRNA U3713
SNORD8	mgU6-53	14q11	CHD8	6.937E-01	U6 snRNA A53
SNORD116-23	HBII-85-23	15q11.2	SNRPN	3.017E-02	unknown
SNORD116-1	HBII-85-1	15q11.2	SNRPN	1.364E-01	unknown
SNORD116-29	HBII-85-29	15q11.2	SNRPN	8.127E-01	unknown
SNORD60	U60	16p13	LOC100507303	A ^a	28S rRNA G4340
SNORD104	U104	17q23	ORGUL028719	A ^a	28S rRNA C1327
SCARNA17	mgU12-22/U4-8	18q21.1	I ^b		U4 snRNA C8 and U12 snRNA G22
SNORA68	U68	19p13	RPL18A	A ^a	28S rRNA U4393
SNORD37	U37	19p13.3	EEF2	1.845E-03	28S rRNA A3697
SNORD34	U34	19q13	RPL13A	A ^a	28S rRNA U2824
SNORA71C	U71C	20q11.23	LOC388796	1.910E-01	18S rRNA U406
SNORA36A	ACA36	Xq28	DKC1	1.561E-03	18S rRNA U1244 and 18S rRNA U105

Abbreviations: scaRNA small Cajal body-specific RNA, snoRNA small nucleolar RNA. ^aprobe not present onto Human Gene 1.0 ST arrays; ^bIndependent transcriptional unit; snoRNA significantly correlating with corresponding host gene is typed in bold.

Table 4 SnoRNAs with significant predictive value related to PFS in the univariate log-rank test

Variable	HR	Lo 95% CI	Up 95% CI	p-val
SNORD1A	0.47	0.27	0.82	6.03 E-03
SNORD56	0.5	0.3	0.83	6.08 E-03
SNORA70F	0.4	0.24	0.66	2.41 E-04
SNORD116-18	2.49	1.46	4.27	5.64 E-04
SNORA74A	2.37	1.4	4	9.27 E-04

scaRNAs that significantly discriminate between CLL cells and N, MZ and SM B-cells, might be of relevance in disease pathogenesis. These are SNORA31, -6, -62, and 71C, all of them representing canonical “H/ACA snoRNAs”, which bind to conserved core box H/ACA snoRNP proteins, such as DKC1, GAR1, NHP2 and NOP10, and act mainly as guide RNAs for the site-specific pseudouridylation of specific target rRNA [15]. Notably, all of these ncRNAs were down-regulated in CLL cells (Figure 1B) irrespective of the presence or absence of other genetic lesions (data not shown). Specifically, SNORA31 was significantly down-regulated in association with its host gene *TPT1* (Table 3), which encodes for a critical protein involved in the control of stemness, pluripotency, or tumor reversion [37]. In addition, *TPT1* mRNA is capable of activating the dsRNA-dependent protein kinase PKR, which is in turn critical for the tumor suppressor function of TP53 [37]. At present it is unknown whether SNORA31 down-regulation may have a pathological role *per se*, or whether this down-regulation merely represents a marker of *TPT1* down-regulation. SNORA6 and -62, were both down-regulated in association with their common host gene *RPSA* (Table 3). This gene encodes for a protein that, depending on its folding configuration, may have different cellular activities in specific compartments, that is the ribosomal protein SA or the laminin membrane receptor. Cytometric studies reported that the immature laminin receptor which, unlike the mature receptor, is not acylated, is specifically expressed on the surface of CLL B-cells but not in N,

Table 5 Multivariate analysis comparing the 2-snoRNAs risk model with prognostic variables in CLLs series

Variable	HR	Lo 95% CI	Up 95% CI	p-val
2-snoRNAs MODEL	2.53	1.48	4.32	0.0007
UM-CLL	1.86	0.92	3.79	0.0854
ZAP-70	1.27	0.69	2.36	0.4411
CD38	2.61	1.43	4.77	0.0018
del11	1.76	0.81	3.83	0.1518
del17	1.41	0.32	6.31	0.6494
12+	1.05	0.52	2.15	0.8867




Figure 2 PFS of patients grouped according to the snoRNAs-based model. Kaplan-Meier curves of the 2 groups defined by the 2-snoRNAs model identifying a low-risk group characterized by the low expression of both snoRNAs and a high risk group characterized by the high expression of at least one of the two snoRNAs. The high risk group has a median PFS of 39 months.

GC, or SM B-lymphocytes from normal tonsils. Moreover, its expression correlated with mutated *IGHV* status predicting a favorable prognosis in CLL [38]. These data are in apparent conflict with ours, although it is possible that down-regulation of the *RPSA* gene does not affect the translated gene fraction folded as immature laminin receptor, but rather the co-regulated expression of SNORA6 and -62. Finally, CLL cells significantly down-regulated SNORA71C located in a cluster at chromosome 20q11 including SNORA71A, -71B, and -71D.

Our data based on unsupervised analyses suggest an heterogeneous pattern of sno/scaRNA expression profiles within the major CLL subgroups classified according to biological, molecular and cytogenetic markers. This is different from the evidence in MM showing specific sno/scaRNA expression patterns associated with distinct molecular subgroups of the disease [19]. However, supervised analyses demonstrated specific, albeit limited, signatures of sno/scaRNA expression in distinct molecular and genetic CLL groups (Table 2). To note, SNORA70F was found consistently down-regulated in patients associated with adverse prognostic markers, such as unmutated *IGHV*, ZAP70 and CD38 positivity, 12+, and del11. SNORA70F is located within the first intron of the *COBLL1* gene, the expression of which correlates significantly with that of

SNORA70F in our dataset (Table 3). *COBLL1* is down-regulated in UM-CLLs [39] as well as in CLL with a poor prognosis in general [40]. The exact function of the *COBLL1*-encoded protein is still unknown, although data have suggested an involvement in mid-brain neural tube closure [41]. Moreover, *COBLL1* is a negative regulator of apoptosis in malignant mesothelioma cells and its expression is associated with a relatively better prognosis [42]. Finally, we provided evidence that patients with del11 or 12+ deregulated sno/scaRNAs located in the respective altered chromosome; in particular, 12+ samples exhibited a significant up-regulation of snoRNAs host genes as well (Table 2), supporting the notion that the gene dosage effects brought about by this lesion may have a pathogenetic value [43].

With regards to the potential clinical relevance of this specific ncRNA family in cancer, recent reports indicated the association of SNORD25, SNORD27, SNORD30, and SNORD31 with progression from smoldering to symptomatic MM [18] and the over-expression of SNORD71 in peripheral T-cell Lymphoma with favorable outcome [22]. In our study, we generated a 2-snoRNAs risk model which appears to be able to distinguish two different prognostic groups in our series of Binet stage A CLL patients, independently of all the other known molecular markers. Specifically, the high-risk group was characterized by the high expression of at least one of the two snoRNAs, SNORA74A and SNORD116-18.

Little is known about SNORA74A, which is found to be processed from the second intron of a long pre-mRNA-like transcript, termed precursor U19H RNA. At least five transcripts are obtained by alternative splicing of the long *U19H* gene, and only one form (approximately 2%) encodes for a protein, MATR3, involved in mRNA stabilization [44,45]. This evidence may explain why SNORA74A expression does not correlate with that of *MATR3*, a phenomenon also observed in MM patients [19]. SNORD116-18 belongs to a cluster of 29 highly similar copies that, together with the SNORD115 cluster, are tandemly-arranged within the introns of the *SNURF-SNRPN* transcript, which contains at least 148 exons spanning more than 460 kb on chromosome 15q11. This genomic region is known to be affected by minimal deletions associated with the Prader-Willi syndrome (PWS) [46]. The expression of *SNURF-SNRPN*, as well as that of other several genes in this region, is finely regulated by a bipartite imprinting center (IC) which silences most maternal genes of the PWS critical region allowing the *SNURF-SNRPN* pre-mRNA to be expressed only from the paternal allele. However, mechanisms other than IC methylation may contribute to the deregulated expression of SNORD116 in MM [19]. To note, SNORD116-18 belongs to a subgroup of so-called "orphan" sno/scaRNAs which lack apparent complementarities to cellular RNAs.

These molecules may play a role in the regulation of alternative splicing mRNAs, as demonstrated for murine SNORD115 which is processed to a shorter form binding to complementary target sequences on the *HTR2C* pre-mRNA for the correct alternative splicing of the serotonin receptor mRNA [47]. A role in the 3' processing of selected snoRNAs has also been proposed for SCARNA22 which is deregulated in MM in association with its host gene *MMSET*, involved in the t(4,14) chromosomal translocation [17]. A similar function could be suggested for SNORD116 variants, as also predicted by the recent available snoTARGET open source [48]. In this perspective, it is conceivable that SNORD116-18 deregulation might also have a role in CLL cell since the involvement of uncorrected splicing mechanisms in CLL pathology is supported by increasing evidence [40,49]. Unfortunately, the lack of either independent publicly available datasets or some standardizable methodology prevented the identified 2-snoRNA model from being considered a pure classifier; however, our results provided important indication on the possible role of non-coding RNA in the prognosis of CLL, and prompt for further investigations.

Conclusions

In conclusion, our data extend the current view of ncRNA deregulation in cancer pointing to the potential relevance of the sno/scaRNA family in the context of CLL which may contribute to discover novel putative molecular markers associated with the disease.

Additional files

Additional file 1: Supplemental Methods.

Additional file 2: CD19+ tonsil B cells were stained for IgD/CD38 expression. Three different populations were gated to obtain: IgD^{bright}CD38⁻CD27⁻naïve (N) B cells; IgD⁻CD38⁺ (GC, germinal center) and IgD^{-low}CD38⁻CD27⁺ (memory B cells). The latter were further separated into IgM⁺ (MZ, analogous to marginal zone-like B cells) and IgM⁻ (SM, switched memory) B cells.

Additional file 3: Plots of the density distributions of SNORA74A and SNORD116-18 expression across 191 samples. Green and orange dots distinguish low and high expression whereas the vertical dot lines indicate the thresholds.

Additional file 4: Supervised analysis comparing peripheral B-cell and CLL samples. List of the 103 differentially expressed sno/scaRNAs identified by a high stringent supervised analysis between peripheral B-cell and CLL patients (SAM, q-value 0).

Additional file 5: List of sno/scaRNA genes varying 1.5-fold from the mean across the dataset. Sno/scaRNAs are ordered according to the *p*-value obtained with the global test, that measured the association (positive or negative, as indicated) between each of the 80 most variable sno/scaRNAs and Progression Free Survival (PFS). The 5 sno/scaRNAs showing a significant association with PFS ($P < .05$) were highlighted in pink.

Additional file 6: Unsupervised analysis. Hierarchical agglomerative clustering of the samples using the 80 most variable sno/scaRNAs (see Additional file 5, patients in columns, snoRNAs in rows) was performed adopting Pearson and average as distance and linkage methods, respectively. The color scale bar represents the relative sno/

scaRNA expression changes normalized by the standard deviation. The patients' molecular characteristics are shown above the matrix; n indicates unavailable information.

Additional file 7: SNORA70F expression levels in the cohort of 211 CLL samples. The patients' molecular characteristics are shown below the histogram; each patients were assigned a score (1–5) according to the number of adverse clinical and molecular characteristic in the same patients. Cumulative adverse characteristic in the same sample (score 5) is associated with the lower SNORA70F expression.

Additional file 8: List of the sno/scaRNAs significantly correlating with matching host genes (Kendall corrected q-value < .05).

Additional file 9: Multivariate analysis. Multivariate Cox regression analysis testing the independence of the 5 snoRNAs significant associated with PFS from known predictive factors in CLL as covariates.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Contributions: DR analyzed the data, performed Q-RT-PCR, and wrote the manuscript; LM generated gene expression profiling data and analyzed the data; GT and LA performed statistical and integrative analyses; SF and GC performed FISH; SM, CM, MC, MG, SB, and GC performed the characterization of CLL samples for prognostic markers and cell purification; SM, CM, and DR performed B-cell subsets preparation and cell sorting; MN, FM, MF, AGR, and PT critically reviewed the manuscript; AN designed the study and wrote the manuscript. All authors approved the final version of the manuscript.

Acknowledgments

This work was supported by: Associazione Italiana Ricerca sul Cancro (AIRC) grant 5xmille no. 9980, 2010–15 to PT, AN, FM, MF, and MN, and AIRC IG10136 to A.N and IG10492 to M.F; Ministero Italiano dell' Istruzione, Università e Ricerca (MIUR) (2009PKMYA2) to A.N. Recchia A.G. is supported by a grant from Fondazione 'Amelia Scorza' onlus, Cosenza. Colombo M is supported by AIRC grant to M.F; Bossio S, Matis S and Massucco C are supported by a AIRC 5xmille grant.

Author details

¹Department of Clinical Sciences and Community Health, University of Milano, Milano, Italy. ²SS Molecular Diagnostics, IRCCS S. Martino-IST, Genova, Italy. ³Department of Clinical Sciences and Community Health, University of Milan, Hematology 1 CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, F. Sforza, 35-20122, Milano, Italy. ⁴U.O.C. di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy. ⁵Scientific Direction, IRCCS S. Martino-IST, Genova, Italy. ⁶Department of Pathology IRCCS S. Martino-IST, Genova, Italy. ⁷Department of Experimental and Clinical Medicine, University of Ferrara, Ferrara, Italy. ⁸Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.

Received: 22 July 2013 Accepted: 2 September 2013

Published: 3 September 2013

References

- Chiorazzi N, Rai KR, Ferrarini M: **Chronic lymphocytic leukemia.** *N Engl J Med* 2005, **352**:804–815.
- Zwiebel JA, Cheson BD: **Chronic lymphocytic leukemia: staging and prognostic factors.** *Semin Oncol* 1998, **25**:42–59.
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: **Clinical staging of chronic lymphocytic leukemia.** *Blood* 1975, **46**:219–234.
- Binet JL, Vaugier G, Dighiero G, D'Atthis P, Charron D: **Investigation of a new parameter in chronic lymphocytic leukemia: the percentage of large peripheral lymphocytes determined by the hemalog D. Prognostic significance.** *Am J Med* 1977, **63**:683–688.
- Kay NE, Shanafelt TD: **Prognostic factors in chronic lymphocytic leukemia.** *Curr Hematol Malig Rep* 2007, **2**:49–55.
- Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E: **ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.** *N Engl J Med* 2003, **348**:1764–1775.
- Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N: **Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.** *Blood* 1999, **94**:1840–1847.
- Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK: **Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.** *Blood* 1999, **94**:1848–1854.
- Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH, Heerema NA: **Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.** *Cancer Res* 2003, **63**:36–38.
- Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S: **p53 Gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.** *Blood* 1995, **85**:1580–1589.
- Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P: **Genomic aberrations and survival in chronic lymphocytic leukemia.** *N Engl J Med* 2000, **343**:1910–1916.
- Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T: **Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.** *Leukemia* 2007, **21**:2442–2451.
- Stilgenbauer S, Bullinger L, Lichter P, Dohner H: **Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.** *Leukemia* 2002, **16**:993–1007.
- Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS: **Non-coding RNAs: regulators of disease.** *J Pathol* 2010, **220**:126–139.
- Kiss T: **Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions.** *Cell* 2002, **109**:145–148.
- Williams GT, Farzaneh F: **Are snoRNAs and snoRNA host genes new players in cancer?** *Nat Rev Cancer* 2012, **12**:84–88.
- Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH: **Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.** *J Clin Invest* 2012, **122**:2793–2806.
- Lopez-Corral L, Mateos MV, Corchete LA, Sarasquete ME, la RJ D, De AF, Lahuerta JJ, Garcia-Sanz R, San Miguel JF, Gutierrez NC: **Genomic analysis of high risk smoldering multiple myeloma.** *Haematologica* 2012, **97**:1439–1443.
- Ronchetti D, Todoerti K, Tuana G, Agnelli L, Mosca L, Lionetti M, Fabris S, Colapietro P, Miozzo M, Ferrarini M, Tassone P, Neri A: **The expression pattern of small nucleolar and small cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.** *Blood Cancer J* 2012, **2**:e96.
- Teittinen KJ, Laiho A, Uusimäki A, Pursiheimo JP, Gyenesi A, Lohi O: **Expression of small nucleolar RNAs in leukemic cells.** *Cell Oncol (Dordr)* 2013, **36**:55–63.
- Valleron W, Laprevotte E, Gautier EF, Quelen C, Demur C, Delabesse E, Agirre X, Prosper F, Kiss T, Brousset P: **Specific small nucleolar RNA expression profiles in acute leukemia.** *Leukemia* 2012, **26**:2052–2060.
- Valleron W, Ysebaert L, Berquet L, Fataccioli V, Quelen C, Martin A, Parrens M, Lamant L, De LL, Gisselbrecht C, Gaulard P, Brousset P: **Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma.** *Blood* 2012, **8**:3997–4005.
- Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR: **National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.** *Blood* 1996, **87**:4990–4997.
- Cutrona G, Colombo M, Matis S, Reverberi D, Dono M, Tarantino V, Chiorazzi N, Ferrarini M: **B lymphocytes in humans express ZAP-70 when activated in vivo.** *Eur J Immunol* 2006, **36**:558–569.
- Cutrona G, Colombo M, Matis S, Fabbri M, Spriano M, Callea V, Vigna E, Gentile M, Zupo S, Chiorazzi N, Morabito F, Ferrarini M: **Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.** *Haematologica* 2008, **93**:413–422.
- Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi DG, Morabito F, Ferrarini M, Neri A: **Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.** *Genes Chromosomes Cancer* 2008, **47**:871–879.

27. Maura F, Cutrona G, Fabris S, Colombo M, Tuana G, Agnelli L, Matis S, Lionetti M, Gentile M, Recchia AG, Di RF, Musolino C, Ilariucci F, Di RN, Pesce E, Molica S, Federico M, Cortelezzi A, Morabito F, Ferrarini M: **Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia.** *PLoS One* 2011, **6**:e24313.
28. Morabito F, Cutrona G, Gentile M, Matis S, Todoerti K, Colombo M, Sonaglio C, Fabris S, Reverberi D, Megna M, Spriano M, Lucia E, Rossi E, Callea V, Mazzone C, Festini G, Zupo S, Molica S, Neri A, Ferrarini M: **Definition of progression risk based on combinations of cellular and molecular markers in patients with binet stage a chronic lymphocytic leukaemia.** *Br J Haematol* 2009, **146**:44–53.
29. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: **Exploration, normalization, and summaries of high density oligonucleotide array probe level data.** *Biostatistics* 2003, **4**:249–264.
30. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F: **Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data.** *Nucleic Acids Res* 2005, **33**:e175.
31. Sandberg R, Larsson O: **Improved precision and accuracy for microarrays using updated probe set definitions.** *BMC Bioinforma* 2007, **8**:48.
32. Tusher VG, Tibshirani R, Chu G: **Significance analysis of microarrays applied to the ionizing radiation response.** *Proc Natl Acad Sci USA* 2001, **98**:5116–5121.
33. Schadt EE, Li C, Ellis B, Wong WH: **Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data.** *J Cell Biochem Suppl* 2001, **37**:120–125.
34. Xie J, Zhang M, Zhou T, Hua X, Tang L, Wu W: **Sno/scaRNAbase: a curated database for small nucleolar RNAs and cajal body-specific RNAs.** *Nucleic Acids Res* 2007, **35**:D183–D187.
35. Chiorazzi N, Ferrarini M: **Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.** *Blood* 2011, **117**:1781–1791.
36. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, Kuppers R: **Cellular origin and pathophysiology of chronic lymphocytic leukemia.** *J Exp Med* 2012, **209**:2183–2198.
37. Amson R, Pece S, Marine JC, Di Fiore PP, Teleman A: **TPT1/ TCTP-regulated pathways in phenotypic reprogramming.** *Trends Cell Biol* 2013, **23**:37–46.
38. Friedrichs B, Siegel S, Reimer R, Barsoum A, Coggin J Jr, Kabelitz D, Heidorn K, Schulte C, Schmitz N, Zeis M: **High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia.** *Leuk Res* 2011, **35**:721–729.
39. Abruzzo LV, Barron LL, Anderson K, Newman RJ, Wierda WG, O'Brien S, Ferrajoli A, Luthra M, Talwalkar S, Luthra R, Jones D, Keating MJ, Coombes KR: **Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.** *J Mol Diagn* 2007, **9**:546–555.
40. Mansouri L, Gunnarsson R, Sutton LA, Ameer A, Hooper SD, Mayrhofer M, Juliusson G, Isaksson A, Gyllensten U, Rosenquist R: **Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia.** *Am J Hematol* 2012, **87**:737–740.
41. Carroll EA, Gerrelli D, Gasca S, Berg E, Beier DR, Copp AJ, Klingensmith J: **Cordon-bleu is a conserved gene involved in neural tube formation.** *Dev Biol* 2003, **262**:16–31.
42. Gordon GJ, Bueno R, Sugarbaker DJ: **Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.** *BMC Cancer* 2011, **11**:169.
43. Gaidano G, Foa R, La-Favera R: **Molecular pathogenesis of chronic lymphocytic leukemia.** *J Clin Invest* 2012, **122**:3432–3438.
44. Bortolin ML, Kiss T: **Human U19 intron-encoded snoRNA is processed from a long primary transcript that possesses little potential for protein coding.** *RNA* 1998, **4**:445–454.
45. Salton M, Elkon R, Borodina T, Davydov A, Yaspo ML, Halperin E, Shiloh Y: **Matrin 3 binds and stabilizes mRNA.** *PLoS One* 2011, **6**:e23882.
46. Runte M, Huttenhofer A, Gross S, Kiefmann M, Horsthemke B, Buiting K: **The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar RNA species and as an antisense RNA for UBE3A.** *Hum Mol Genet* 2001, **10**:2687–2700.
47. Kishore S, Khanna A, Zhang Z, Hui J, Balwierc PJ, Stefan M, Beach C, Nicholls RD, Zavolan M, Stamm S: **The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing.** *Hum Mol Genet* 2010, **19**:1153–1164.
48. Bazeley PS, Shepelev V, Talebizadeh Z, Butler MG, Fedorova L, Filatov V, Fedorov A: **snoTARGET shows that human orphan snoRNA targets locate close to alternative splice junctions.** *Gene* 2008, **408**:172–179.
49. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S: **SF3B1 And other novel cancer genes in chronic lymphocytic leukemia.** *N Engl J Med* 2011, **365**:2497–2506.

doi:10.1186/1755-8794-6-27

Cite this article as: Ronchetti et al.: Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. *BMC Medical Genomics* 2013 **6**:27.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

